Literature DB >> 29146708

Inflammatory molecule reduction with hydroxyurea therapy in children with sickle cell anemia.

Rhiannon R Penkert1, Julia L Hurwitz1,2, Paul Thomas3, Jason Rosch1, Jola Dowdy4, Yilun Sun5, Li Tang5, Jane S Hankins6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29146708      PMCID： PMC5792285          DOI： 10.3324/haematol.2017.177360

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  18 in total

1.  GMI-1070, a novel pan-selectin antagonist, reverses acute vascular occlusions in sickle cell mice.

Authors:  Jungshan Chang; John T Patton; Arun Sarkar; Beat Ernst; John L Magnani; Paul S Frenette
Journal:  Blood       Date:  2010-05-27       Impact factor: 22.113

2.  Simvastatin reduces vaso-occlusive pain in sickle cell anaemia: a pilot efficacy trial.

Authors:  Carolyn Hoppe; Eufemia Jacob; Lori Styles; Frans Kuypers; Sandra Larkin; Elliott Vichinsky
Journal:  Br J Haematol       Date:  2017-03-28       Impact factor: 6.998

3.  Hydroxyurea therapy of a murine model of sickle cell anemia inhibits the progression of pneumococcal disease by down-modulating E-selectin.

Authors:  Jeffrey D Lebensburger; Thad Howard; Yunming Hu; Tamara I Pestina; Geli Gao; Melissa Johnson; Stanislav S Zakharenko; Russell E Ware; Elaine I Tuomanen; Derek A Persons; Jason W Rosch
Journal:  Blood       Date:  2011-11-30       Impact factor: 22.113

4.  Decrease of very late activation antigen-4 and CD36 on reticulocytes in sickle cell patients treated with hydroxyurea.

Authors:  L A Styles; B Lubin; E Vichinsky; S Lawrence; M Hua; S Test; F Kuypers
Journal:  Blood       Date:  1997-04-01       Impact factor: 22.113

5.  Decreased plasma endothelin-1 levels in children with sickle cell disease treated with hydroxyurea.

Authors:  Claudine Lapouméroulie; Malika Benkerrou; Marie Hélène Odièvre; Rolande Ducrocq; Manuel Brun; Jacques Elion
Journal:  Haematologica       Date:  2005-03       Impact factor: 9.941

6.  Key endothelial cell angiogenic mechanisms are stimulated by the circulating milieu in sickle cell disease and attenuated by hydroxyurea.

Authors:  Flavia C M Lopes; Fabiola Traina; Camila B Almeida; Flavia C Leonardo; Carla F Franco-Penteado; Vanessa T Garrido; Marina P Colella; Raquel Soares; Sara T Olalla-Saad; Fernando F Costa; Nicola Conran
Journal:  Haematologica       Date:  2015-03-13       Impact factor: 9.941

7.  Normal levels of soluble E-selectin, soluble intercellular adhesion molecule-1 (sICAM-1), and soluble vascular cell adhesion molecule-1 (sVCAM-1) decrease with age.

Authors:  M C Nash; A M Wade; V Shah; M J Dillon
Journal:  Clin Exp Immunol       Date:  1996-01       Impact factor: 4.330

8.  Increased adhesive properties of eosinophils in sickle cell disease.

Authors:  Andreia Averci Canalli; Nicola Conran; André Fattori; Sara T O Saad; Fernando Ferreira Costa
Journal:  Exp Hematol       Date:  2004-08       Impact factor: 3.084

9.  Modulation of erythroid adhesion receptor expression by hydroxyurea in children with sickle cell disease.

Authors:  Marie-Hélène Odièvre; Viviane Bony; Malika Benkerrou; Claudine Lapouméroulie; Corinne Alberti; Rolande Ducrocq; Evelyne Jacqz-Aigrain; Jacques Elion; Jean-Pierre Cartron
Journal:  Haematologica       Date:  2008-03-05       Impact factor: 9.941

10.  Altered levels of cytokines and inflammatory mediators in plasma and leukocytes of sickle cell anemia patients and effects of hydroxyurea therapy.

Authors:  C Lanaro; C F Franco-Penteado; D M Albuqueque; S T O Saad; N Conran; F F Costa
Journal:  J Leukoc Biol       Date:  2008-11-12       Impact factor: 4.962
View more
  5 in total

Review 1.  Blood rheology biomarkers in sickle cell disease.

Authors:  Madeleine Lu; Minke Ae Rab; Sergey S Shevkoplyas; Vivien A Sheehan
Journal:  Exp Biol Med (Maywood)       Date:  2020-01-16

2.  Longitudinal effect of disease-modifying therapy on tricuspid regurgitant velocity in children with sickle cell anemia.

Authors:  Parul Rai; Vijaya M Joshi; Jason F Goldberg; Amber M Yates; Victoria I Okhomina; Rhiannon Penkert; Kenneth I Ataga; Guolian Kang; Jane S Hankins
Journal:  Blood Adv       Date:  2021-01-12

3.  Hydroxyurea alters circulating monocyte subsets and dampens its inflammatory potential in sickle cell anemia patients.

Authors:  Caroline C Guarda; Paulo S M Silveira-Mattos; Sètondji C M A Yahouédéhou; Rayra P Santiago; Milena M Aleluia; Camylla V B Figueiredo; Luciana M Fiuza; Suellen P Carvalho; Rodrigo M Oliveira; Valma M L Nascimento; Nívea F Luz; Valéria M Borges; Bruno B Andrade; Marilda S Gonçalves
Journal:  Sci Rep       Date:  2019-10-15       Impact factor: 4.379

4.  Hypothesis: Low Vitamin A and D Levels Worsen Clinical Outcomes When Children with Sickle Cell Disease Encounter Parvovirus B19.

Authors:  Rhiannon R Penkert; Melissa Azul; Robert E Sealy; Bart G Jones; Jola Dowdy; Randall T Hayden; Li Tang; A Catharine Ross; Jane S Hankins; Julia L Hurwitz
Journal:  Nutrients       Date:  2022-08-19       Impact factor: 6.706

5.  Polymorphisms in Inflammatory Genes Modulate Clinical Complications in Patients With Sickle Cell Disease.

Authors:  Karina Tozatto-Maio; Robert Girot; Indou Deme Ly; Ana Cristina Silva Pinto; Vanderson Rocha; Francisco Fernandes; Ibrahima Diagne; Yahia Benzerara; Carla L Dinardo; Julia Pavan Soler; Simone Kashima; Itauá Leston Araujo; Chantal Kenzey; Guilherme H H Fonseca; Evandra S Rodrigues; Fernanda Volt; Luciana Jarduli; Annalisa Ruggeri; Christina Mariaselvam; Sandra F M Gualandro; Hanadi Rafii; Barbara Cappelli; Felipe Melo Nogueira; Graziana Maria Scigliuolo; Renato Luiz Guerino-Cunha; Kelen Cristina Ribeiro Malmegrim; Belinda P Simões; Eliane Gluckman; Ryad Tamouza
Journal:  Front Immunol       Date:  2020-09-04       Impact factor: 7.561
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.